Cerity Partners LLC Buys 43,511 Shares of Stryker Corporation $SYK

Cerity Partners LLC boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 16.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 314,580 shares of the medical technology company’s stock after acquiring an additional 43,511 shares during the quarter. Cerity Partners LLC’s holdings in Stryker were worth $124,465,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Consolidated Portfolio Review Corp boosted its stake in shares of Stryker by 4.2% during the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after purchasing an additional 26 shares during the period. Princeton Global Asset Management LLC boosted its position in Stryker by 16.9% during the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock valued at $71,000 after buying an additional 26 shares during the period. Sunflower Bank N.A. boosted its position in Stryker by 4.0% during the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after buying an additional 27 shares during the period. Pitti Group Wealth Management LLC grew its holdings in Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock worth $341,000 after acquiring an additional 27 shares during the last quarter. Finally, Sachetta LLC increased its position in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Down 0.1%

NYSE SYK opened at $363.82 on Friday. The stock’s 50 day moving average is $368.34 and its 200 day moving average is $379.39. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $139.13 billion, a PE ratio of 47.81, a P/E/G ratio of 2.58 and a beta of 0.89. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares of the company’s stock, valued at $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on SYK. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Rothschild Redb upgraded Stryker to a “hold” rating in a research report on Thursday, September 18th. UBS Group set a $408.00 target price on Stryker in a report on Monday, October 13th. Rothschild & Co Redburn assumed coverage on shares of Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target on the stock. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a report on Friday, November 14th. Twelve investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $433.78.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.